1. Long-term first-in-man Phase I/II study of an adjuvant dendritic cell vaccine in patients with high-risk prostate cancer after radical prostatectomy
- Author
-
Svein Dueland, Karol Axcrona, Ulrika Axcrona, Lisbeth Skoge, Rolf Inge Skotheim, Stein Sæbøe-Larssen, Dolores J. Schendel, Dag Josefsen, Gunnar Kvalheim, Steinar Aamdal, Iris Bigalke, Guri Solum, Anne Merete Aaland Tryggestad, Tor Åge Myklebust, Bjørn Brennhovd, Else Marit Inderberg, Wolfgang Lilleby, Turid Kirsti Hønnåshagen, and Richard W Olaussen
- Subjects
Oncology ,Male ,medicine.medical_specialty ,Urology ,medicine.medical_treatment ,Cancer Vaccines ,Time ,Prostate cancer ,Internal medicine ,Outcome Assessment, Health Care ,medicine ,Adjuvant therapy ,Clinical endpoint ,Secondary Prevention ,Humans ,Neoplasm Metastasis ,Prostatectomy ,Vaccines, Synthetic ,business.industry ,Incidence (epidemiology) ,breakpoint cluster region ,Prostate ,Prostatic Neoplasms ,Dendritic Cells ,Middle Aged ,Prostate-Specific Antigen ,medicine.disease ,Survival Analysis ,Vaccination ,business ,Adjuvant ,Biomarkers - Abstract
Background Patients with high-risk prostate cancer (PC) can experience biochemical relapse (BCR), despite surgery, and develop noncurative disease. The present study aimed to reduce the risk of BCR with a personalized dendritic cell (DC) vaccine, given as adjuvant therapy, after robot-assisted laparoscopic prostatectomy (RALP). Methods Twelve weeks after RALP, 20 patients with high-risk PC and undetectable PSA received DC vaccinations for 3 years or until BCR. The primary endpoint was the time to BCR. The immune response was assessed 7 weeks after surgery (baseline) and at one-time point during the vaccination period. Results Among 20 patients, 11 were BCR-free over a median of 96 months (range: 84-99). The median time from the end of vaccinations to the last follow-up was 57 months (range: 45-60). Nine patients developed BCR, either during (n = 4) or after (n = 5) the vaccination period. Among five patients diagnosed with intraductal carcinoma, three experienced early BCR during the vaccination period. All patients that developed BCR remained in stable disease within a median of 99 months (range: 74-99). The baseline immune response was significantly associated with the immune response during the vaccination period (p = 0.015). For patients diagnosed with extraprostatic extension (EPE), time to BCR was longer in vaccine responders than in non-responders (p = 0.09). Among 12 patients with the International Society of Urological Pathology (ISUP) grade 5 PC, five achieved remission after 84 months, and all mounted immune responses. Conclusion Patients diagnosed with EPE and ISUP grade 5 PC were at particularly high risk of developing postsurgical BCR. In this subgroup, the vaccine response was related to a reduced BCR incidence. The vaccine was safe, without side effects. This adjuvant first-in-man Phase I/II DC vaccine study showed promising results. DC vaccines after curative surgery should be investigated further in a larger cohort of patients with high-risk PC.
- Published
- 2021